SAFETY OF AUTOLOGOUS MARROW STROMAL CELLS AFTER STROKE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. BRIEF EXPLANATION OF RESEARCH PROJECT--This study will be a Phase I dose-escalation trial to evaluate the safety of autologous mesenchymal stromal cell (MSC) transfusion in patients with acute ischemic stroke. Stroke remains the leading cause of adult disability in the U.S. Most patients do not access healthcare early enough to benefit from hyperacute stroke therapies. In animal models of stroke, administration of MSC days after infarct has been associated with improved behavioral outcome. MSC have been found to be safe in several safety studies of humans with non-cerebrovascular diagnoses. MSC may therefore represent a treatment that can improve outcome in human stroke patients with a wide time window for intervention. The specific aims will evaluate whether the morbidity and mortality rates among patients receiving this treatment are higher than expected according to specific primary and secondary endpoints. The primary endpoint focuses on mortality and major thrombotic/infectious adverse events 90 days after treatment. The secondary endpoints consider these events over a longer term, and further evaluate potential adverse effects on systemic and neurological function.